Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
Authors
Keywords
Nanomedicine, Nanoparticle, Enhanced permeability retention (EPR), Long/short circulation, Delivery efficiency, Preclinical cancer models, Clinical efficacy and adverse events
Journal
BIOMATERIALS
Volume 275, Issue -, Pages 120910
Publisher
Elsevier BV
Online
2021-06-03
DOI
10.1016/j.biomaterials.2021.120910
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical murine tumor models: a structural and functional perspective
- (2020) Marion V Guerin et al. eLife
- Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers
- (2020) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer
- (2020) Hebao Yuan et al. MOLECULAR PHARMACEUTICS
- What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
- (2020) Duxin Sun et al. ACS Nano
- Kaposi sarcoma
- (2019) Ethel Cesarman et al. Nature Reviews Disease Primers
- Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel
- (2019) Feng Li et al. MOLECULAR PHARMACEUTICS
- Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients
- (2019) Olof Borgå et al. ADVANCES IN THERAPY
- Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumours
- (2018) Qin Dai et al. ACS Nano
- Nanoparticle transport pathways into tumors
- (2018) S. M. Moghimi et al. JOURNAL OF NANOPARTICLE RESEARCH
- Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles
- (2018) Feng Li et al. MOLECULAR PHARMACEUTICS
- Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence
- (2018) Diego Adrianzen Herrera et al. EXPERT OPINION ON PHARMACOTHERAPY
- How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation
- (2018) John P. A. Ioannidis et al. Nature Biomedical Engineering
- Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer
- (2017) Takahisa Yamaguchi et al. ONCOLOGY REPORTS
- Effect of removing Kupffer cells on nanoparticle tumor delivery
- (2017) Anthony J. Tavares et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
- (2017) Guido Giordano et al. WORLD JOURNAL OF GASTROENTEROLOGY
- An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
- (2017) In Hae Park et al. Cancer Research and Treatment
- Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
- (2017) Jane Cullis et al. Cancer Immunology Research
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2016) Robert Z. Orlowski et al. CANCER
- PEG- b -PLA micelles and PLGA- b -PEG- b -PLGA sol–gels for drug delivery
- (2016) Hyunah Cho et al. JOURNAL OF CONTROLLED RELEASE
- To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
- (2016) F. Danhier JOURNAL OF CONTROLLED RELEASE
- Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
- (2016) Michael Untch et al. LANCET ONCOLOGY
- Mechanism of hard-nanomaterial clearance by the liver
- (2016) Kim M. Tsoi et al. NATURE MATERIALS
- Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery
- (2016) Yu Matsumoto et al. Nature Nanotechnology
- Tailoring nanoparticle designs to target cancer based on tumor pathophysiology
- (2016) Edward A. Sykes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of nanoparticle delivery to tumours
- (2016) Stefan Wilhelm et al. Nature Reviews Materials
- Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
- (2015) Hiroshi Maeda ADVANCED DRUG DELIVERY REVIEWS
- Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
- (2015) Nianhang Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents
- (2015) Raquel De Souza et al. JOURNAL OF CONTROLLED RELEASE
- Stable isotope method to measure drug release from nanomedicines
- (2015) Sarah Skoczen et al. JOURNAL OF CONTROLLED RELEASE
- Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
- (2015) Andreas Wicki et al. JOURNAL OF CONTROLLED RELEASE
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly
- (2015) Zhuoyang Fan et al. PLoS One
- High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
- (2014) Oscar Arrieta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer
- (2014) Sheridan M. Hoy DRUGS
- Nanopharmaceuticals (part 1): products on the market
- (2014) Volkmar Weissig et al. International Journal of Nanomedicine
- EPR: Evidence and fallacy
- (2014) Joseph W. Nichols et al. JOURNAL OF CONTROLLED RELEASE
- Cancer nanomedicines: closing the translational gap
- (2014) Alberto Gabizon et al. LANCET
- Investigating the optimal size of anticancer nanomedicine
- (2014) L. Tang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- What nanomedicine in the clinic right now really forms nanoparticles?
- (2014) Sonke Svenson Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
- (2013) U. Prabhakar et al. CANCER RESEARCH
- Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
- (2013) Erika Hamilton et al. Clinical Breast Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
- (2011) H. Cabral et al. Nature Nanotechnology
- Tumor delivery of macromolecular drugs based on the EPR effect
- (2010) Vladimir Torchilin ADVANCED DRUG DELIVERY REVIEWS
- Delivering nanomedicine to solid tumors
- (2010) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors
- (2009) Akinori Nagamitsu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started